The CG-100 clinical study is underway at select sites across the U.S.
If you are a rectal cancer patient between the ages of
22-65 planned to undergo a colorectal surgery
and would like to be considered for the study, click here.
Specifically designed to create a temporary intraluminal bypass
Aims to reduce the rate of diverting stoma by reducing the contact of fecal material with the anastomotic site
CG-100 is limited by U.S. law to investigational use and is not approved for sale or distribution in the US
U.S. office location at 125 Cambridge park Drive, Suite 301 Cambridge, MA 02140
Israeli office location at 21 Atir Yeda St, Kfa Saba, 4464316 Israel